Allergy Asthma Immunol Res.  2018 Mar;10(2):95-96. 10.4168/aair.2018.10.2.95.

Is Omalizumab a Problem-Solving Remedy in Severe Asthma?

• Kim DH
• Jee YK

• KMID: 2402968
• DOI: http://doi.org/10.4168/aair.2018.10.2.95

Abstract

No abstract available.

MeSH Terms

Asthma*
Omalizumab*
Omalizumab

Reference

1. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015; 135:896–902.

2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43:343–373.

3. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, et al. Direct health care costs associated with asthma in British Columbia. Can Respir J. 2010; 17:74–80.

4. Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017; 9:3–14.

5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2017 [Internet]. [place unknown]: Global Initiative for Asthma;2017. cited 2017 Dec 19. Available from: www.ginasthma.org.

6. Lee JH, Lee HY, Jung CG, Ban GY, Shin YS, Ye YM, et al. Therapeutic effect of omalizumab in severe asthma: a real-world study in korea. Allergy Asthma Immunol Res. 2018; 10:121–130.

7. Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013; 50:529–536.

8. Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011; 180:637–641.

9. Israel E, Reddel HK. Severe and Difficult-to-treat asthma in adults. N Engl J Med. 2017; 377:965–976.

10. de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013; 50:296–301.

11. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013; 144:411–419.

12. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015; 136:1476–1485.

13. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med. 2017; 196:985–992.

14. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367:1198–1207.